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Abstract: BACKGROUND Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare, aggressive
type of hematologic precursor malignancy primarily often manifesting in the skin. We sought to provide
a thorough clinical characterisation and report our experience on therapeutic approaches to BPDCN.
METHODS In the present multicentric retrospective study, we collected all BPDCN cases occurring
between 05/1999 and 03/2018 in 10 secondary care centres of the German-Swiss-Austrian cutaneous
lymphoma working group. RESULTS A total of 37 BPDCN cases were identified and included. Al-
most 90% of the patients had systemic manifestations (bone marrow, lymph nodes, peripheral blood)
in addition to skin involvement. The latter presented with various types of cutaneous lesions: nodular
(in more than 2/3) and bruise-like (in 1/3) skin lesions, but also maculopapular exanthema (in circa
1/6). Therapeutically, 22 patients received diverse combinations of chemotherapeutic regimens and/or
radiotherapy. Despite initial responses, all of them ultimately relapsed and died from progressive disease.
Eleven patients underwent hematopoietic stem cell transplantation (HSCT; autologous HSCT n=3, allo-
HSCT n=8). The mortality rate among HSCT patients was only 33.33% with a median survival time
of 60.5 months. CONCLUSION Our study demonstrates the clinical diversity of cutaneous BPDCN
manifestations and the positive development observed after the introduction of HSCT.
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Abstract
Background: Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare, 
aggressive type of hematologic precursor malignancy primarily often manifesting in the 
skin. We sought to provide a thorough clinical characterisation and report our experience 
on therapeutic approaches to BPDCN. 
Methods: In the present multicentric retrospective study, we collected all BPDCN cases 
occurring between 05/1999 and 03/2018 in 10 secondary care centres of the German-
Swiss-Austrian cutaneous lymphoma working group. 
Results: A total of 37 BPDCN cases were identified and included. Almost 90% of the 
patients had systemic manifestations (bone marrow, lymph nodes, peripheral blood) in 
addition to skin involvement. The latter presented with various types of cutaneous 
lesions: nodular (in more than 2/3) and bruise-like (in 1/3) skin lesions, but also 
maculopapular exanthema (in circa 1/6). Therapeutically, 22 patients received diverse 
combinations of chemotherapeutic regimens and/or radiotherapy. Despite initial 
responses, all of them ultimately relapsed and died from progressive disease. Eleven 
patients underwent hematopoietic stem cell transplantation (HSCT; autologous HSCT 
n=3, allo-HSCT n=8). The mortality rate among HSCT patients was only 33.33% with a 
median survival time of 60.5 months. 
Conclusion: Our study demonstrates the clinical diversity of cutaneous BPDCN 
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Introduction
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare aggressive hematological 
malignancy (incidence 0.40-0.45/1,000,000), accounting for 0.44% of all hematological 
malignancies and 0.7% of cutaneous lymphoma cases [1]. Upon its first description in 
1995, BPDCN was designated agranular CD4+ natural killer (NK) cell leukemia due to its 
characteristic surface marker profile (CD3-CD4+CD56+CD15+) and unique agranular 
morphology [2-4]. It subsequently became evident that BPDCN is a neoplasm of 
plasmacytoid dendritic cell (pDC) precursor cells now recognized as a distinct 
category/entity in the 2016 revision of the World Health Organization classification of 
tumours of hematopoietic and lymphoid tissues [5, 6]. 
Skin is the most commonly primarily affected target organ in BPDCN. Cutaneous lesions 
range from plaques and nodules to generalized patches and bruise-like lesions [7]. 
Besides involvement of peripheral blood and bone marrow (BM), found in about 45% of 
the cases, various organs (e.g. central nervous system, lungs, breast, gallbladder) can be 
affected [7-12]. 
Histologically, BPDCN lesions consist of infiltrates of medium-sized blastic cells with 
irregular nuclei. Besides the pDC markers TCL1, CD123 and/or CD303 (BDCA-2) [13], 
BPDCN express CD4 and CD56 (although aberrant phenotypes, i.e. CD4-CD56-, have 
been reported). 
Therapeutic strategies for BPDCN are diverse as there are currently no consensus 
treatment guidelines. Fairly limited success (median survival of only 12-14 months [14, 
15]) was achieved with chemotherapeutic regimens, but more recently, promising results 
have been reported with hematopoietic stem cell transplantation (HSCT) [16, 17]. Several 
studies indicate a curative potential and/or improved survival following both allogeneic 
and autologous HSCT [16, 18, 19]. It is still debatable which one of the two HSCT 
modalities may be superior for the treatment of BPDCN. The benefit of novel agents such 
as the BCL2-inhibitor Venetoclax or the NFkB-pathway inhibitor Bortezomib is currently 
being investigated [20-24].
In the present retrospective multicentric study, we analysed BPDCN cases collected by 
members of the cutaneous lymphoma working group of the Arbeitsgemeinschaft 
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the varying clinical presentations of BPDCN and to describe the current expertise on 










This article is protected by copyright. All rights reserved
Study Design
We conducted a multicentric retrospective study within the German-Austrian-Swiss 
cutaneous lymphoma working group of the ADF. We identified BPDCN cases diagnosed 
between May 1999 and February 2018 in 10 secondary care centres (Supplementary 
Table 1) in Germany (5 centres), Switzerland (1 centre), and Austria (4 centres). 
All identified patients with BPDCN (definition according to the International Classification 
of Diseases, 11th Revision (ICD-11) Code 2A60.5) were included in the study. The study 
was conducted according to the ethical guidelines at the respective institutions and the 
Helsinki Declaration. Data protection according to the EU and Swiss standards was 
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Results
Demographics and patient characteristics
We retrospectively identified a total of 37 classical CD4+/CD123+/CD56+ BPDCN cases 
in 10 centres over a period of 19 years (Table 1, Supplementary Table 1).  The mean age 
at diagnosis was 67.2 ± 14.9 years. 78.4% of the included BPDCN patients were male 
(male-to-female ratio almost 4:1). Male patients were about six years older (68.56 ± 
13.90 years) at the time of diagnosis as compared to female patients (62.39 ± 17.07 
years). 
Diagnosis and manifestations
From a total of 37 patients, more than 90% (n=34) had skin manifestations at the time of 
diagnosis (Table 1). Almost 30% of the patients (n=10) experienced fever, night sweats, 
and/or weight loss (B symptoms). Three patients without skin manifestations presented 
with B symptoms only. About 90% of the patients (n=33) had additional organ 
involvement at the time of diagnosis, defined by confirmed invasion by blastic pDC 
precursors at the time of diagnosis. Such involvement included bone marrow (BM; 
59.46%) or peripheral blood (PB; 29.73%). 27.03% of the patients presented with 
lymphadenopathy and 21.62% with splenomegaly. The mean time lapse between 
symptom onset and diagnosis, documented for 20 patients, was 9 weeks (range 4 - 24 
weeks).
Characterisation of skin lesions
Regarding the nature of cutaneous manifestations, bruise-like lesions (haematoma, 
purpura and petechia), patches, erythematous to livid nodules, and maculopapular 
rashes were reported (Figure 1A-C). About 75% of the patients had nodules and/or 
plaques (n=28). Approximately 35% exhibited bruise-like skin lesions (n=13) or 
maculopapular exanthema (n=13), respectively. Almost half (45.95%) of the patients 
presented with more than one type of skin lesion (Supplementary Figure 1). Importantly, 
the time lapse between symptom onset and diagnosis was longer in patients with bruise-
like as compared to nodular or plaque-like lesions (Table 2). This diagnostic delay was 
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Regardless of the nature of cutaneous manifestations, pruritus was rarely reported (only 
ca. 5% of all patients). Concerning the distribution of skin lesions (Figure 2), trunk 
involvement was most frequent (n=29). The extremities were affected in about 50% of the 
cases (n=19). The face commonly exhibited maculopapular rashes (53.80%) but was 
mostly spared in other types of skin lesions. One patient exhibited BPDCN lesions in the 
nasal mucosa.
Comorbidities: malignancies
Almost 40% of the patients (n=14) had additional concomitant malignancies, which were 
either haematological (n=7) or non-haematological (n=8; 7 patients). None of the patients 
concurrently had an additional hematological and non-hematological malignancy, but one 
patient had concurrently two non-hematological malignancies - a melanoma and a 
mammary carcinoma. Haematological malignancies included acute lymphoblastic 
leukemia (n=2), acute myeloid leukemia (n=1), Hodgkin’s lymphoma (n=1), non-Hodgkin 
lymphoma (n=1), and myelodysplastic syndrome (n=2). There was no association 
between BPDCN and a particular type of non-haematological malignancy (Table 3). 
Treatment regimens of two decades
In terms of first-line treatments, about 70% (n=22) of the patients received a broad range 
of chemotherapy regimens (Table 1, Supplementary Table 2). Radiotherapy alone or in 
combination with systemic agents was applied in 3 patients. Eleven patients underwent 
HSCT (more details below). For three patients no disease specific treatment was 
recorded, either due to lost to follow-up (one patient) or due to fulminant disease 
progression, which necessitated immediate palliative care (two patients). 
Our 16 patients treated after 2008, i.e. half-time of our retrospective analysis (Figure 2A), 
had a significantly better overall survival as compared to those treated in and prior 2008: 
20.3 months (range: 1.6-76.2 months), with six patients still alive, versus 10.7 months 
(range: 3.87 – 25.3 months). These differences could not be attributed to age, gender or 
skin lesion type / organ involvement. In contrast, there were major differences in terms of 
treatment approaches between the prior/after 2008 cohorts: 11 out of 16 patients treated 
after 2008 received HSCT (vs. none of those prior 2008), which was associated with 
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Survival following chemotherapies
The majority of patients responded to first-line chemotherapies (listed in Supplementary 
Table 2): three patients achieved complete remission, 11 partial remission and two had 
stable disease (Table 1). Progressive disease was observed in six patients. All patients 
eventually relapsed, with a mean progression-free survival of less than a year (6.5 
months; range: 0.5 – 19.7 months). Regarding the type of chemotherapy (Supplementary 
Table 2), five patients received an AML-, two an ALL- and twelve a lymphatic lymphoma 
regimen. Patients receiving the latter had a better overall and progression-free survival 
(Figure 2B).
Second-line treatments included alternate chemotherapeutic regimens, single-agent or 
combination therapies, and radiation (Supplementary Table 2). Twelve patients with a 
relapse did not receive a second-line treatment. All patients solely undergoing 
chemotherapies and/or radiotherapy eventually died from progressive disease. Mean 
overall survival was 8.67 months (range: 0.5 - 23.9 months). 
Therapeutic success of allogeneic and autologous HSCT
A total of 11 patients underwent HSCT, all of them were treated after 2008: eight 
received allogeneic and three autologous HSCT (allo-HSCT: n=8; auto-HSCT: n=3; Table 
3). Patients receiving auto-HSCT were older (75.3 ± 12.13 years) as compared to allo-
HSCT patients (46.6 ± 15.54 years). The male-to-female ratio was 2:1 for auto-HSCT and 
3:1 for allo-HSCT, respectively. The mortality-rate among HSCT patients was 33.33% 
with no difference between allo- and auto-HSCT recipients (2 allo-HSCT recipients were 
lost to follow-up and thus excluded from the analysis). 
As for the auto-HSCT patients, one patient relapsed within five months post-HSCT and 
died from progressive disease despite a salvage therapy with hydroxyurea. At the study 
closing date (1st of July 2019), the other two patients were still in complete remission and 
alive, with a follow-up of 174 and 884 days, respectively. Of the allo-HSCT recipients, two 
died within eight months post-HSCT (one from therapy-refractory graft-versus-host 
disease, for the second patient the cause of death was not reported). Two allo-HSCT 
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(various lapses of follow-up, i.e. between 156 and 2253 days post-HSCT) at least until 
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Discussion
BPDCN is a very rare and aggressive haematological malignancy manifesting primarily 
mainly in the skin and presenting a major therapeutic challenge. This retrospective study 
encompassing a time period of approximately two decades reports on our experience 
with BPDCN patients from 10 centres belonging to the German-Austrian-Swiss network 
of cutaneous lymphoma. Herewith, we provide a thorough description of the clinical 
presentation of BPDCN and describe our experience with BPDCN treatment regimens, 
with an emphasis on HSCT.
Our cohort of 37 BPDCN patients had a male:female ratio of 4:1, i.e. double the 
percentage of males as compared to previous reports. BPDCN skin manifestations are 
the most common primary manifestation of the disease (in more than 90% of our 
patients) and highly diverse. Clinical recognition and biopsy of cutaneous lesions can 
enable an early diagnosis, which is clinically relevant, given the highly aggressive course 
of the disease. As reflected in our patient cohort, BPDCN lesions can be nodular, bruise-
like or maculopapular in nature. The majority of our patients had nodules or plaques, 
similar to what has been reported [25, 26]). In contrast, we had more patients with bruise-
like lesions (ca. one third) than in previous studies [25]. In addition, our study points out 
that almost half of the patients have more than one type of skin lesions. The longer time 
lapse between symptom onset and diagnosis among patients with bruise-like skin lesions 
underlines the difficulty to recognize this type of manifestation and the importance to 
consider BPDCN as a differential diagnosis of unclear cutaneous lesions and when 
suspecting cutaneous lymphoma and/or leukaemia cutis. 
Involvement of at least one additional organ, i.e. BM, blood or lymph nodes, was 
observed in ca. 90% of our patients. None of them had central nervous system 
involvement, the prevalence of which had previously been reported to be 9-26% [25, 27-
29]. Among our patients, those exclusively presenting skin lesions (n=4) did not have a 
better outcome. Although this limited number of patients does not allow for any 
conclusion, our observations differ from previous reports in that there is a slightly (but not 
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The long coverage period (ca. 20 years) of our study reflects the diversity of therapies 
and concurrent differences in patient survival. This can mainly be attributed to the high 
proportion of patients receiving HSCT as a first-line option (11 out of 16).  Previous 
observations show that despite considerable initial response rates, a long-lasting 
response cannot be achieved with chemotherapies. In a previous study [31], the survival 
of bone marrow transplanted BPDCN patients was significantly higher as compared to all 
other therapeutic choices (chemotherapy, radiation). In line with this, Weil et al found 
high-dose therapy followed by allo-HSCT could induce long-term remission, but due to 
the small number of auto-HSCT patients (n=5) did not draw conclusions in this regard 
[16]. Khardfan-Dabaja et al [17] found a lack of efficacy with autologous HSCT (in 8 
patients). In our study, we did not observe outcome-related differences between auto- 
and allo-HSCT. With the low number of cases (3 auto- and 8 allo-HSCT patients) we 
however cannot draw definite conclusions as to this important issue. This needs to be 
addressed in a large prospective trial. 
Taken together, our experience with 37 BPDCN patients demonstrates the spectrum of 
cutaneous manifestations with which BPDCN may present and that especially clearly 
confirms the superiority of HSCT over any type of chemotherapeutic regimen. The search 
for a matching donor for HSCT along with a swift aggressive course of treatment should 
be initiated as soon as diagnosis of BPDCN is confirmed.
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Tables
Table 1. Patient characteristics. 
Clinical Presentation
Demographics





Clinical presentation at diagnosis
Cutaneous involvement, n (%) 34 (91.9)
Nodules and plaques 28 (75.7)
Bruise-like lesions  13 (35.1)
Maculopapular rash 13 (35.1)
Nasal mucosa 1 (2.70)
Pruritus 2 (5.40)
Extracutaneous involvement 33 (89.2)
Peripheral blood 11 (29.7)
Bone marrow 22 (59.5)
Lymphadenopathy 10 (27.0)
Splenomegaly 8 (21.6)
B symptoms 10 (27.0)





















HSCT as first-line treatment 11 (33.3)
Radiation as first-line treatment 2 (6.06)









Average time lapsed between 







Response to first-line 
chemotherapy, n (%)
SD 2 (10.5)
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Table 2. Involvement of body sites among and time lapse to diagnosis.
Type of skin lesion Time to 
diagnosis
Body site involvement (%)
HSCT type





Nodules 5.1 30.0 (n=11) 20.0 86.7 66.7
Plaques 3.8 19.0 (n=7) 30.8 84.6 53.8
Bruise-like lesions 17.3 30.0 (n=11) 15.4 100 76.9
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Table 3. Comorbidities: Malignancies.















Abbreviations: ALL, acute lymphoblastic leukaemia; AML, acute myeloid leukaemia; HL, 
Hodgkin’s lymphoma; NHL, non-Hodgkin lymphoma; MDS, myelodysplastic syndrome.
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Table 4. HSCT recipients.
Sex Age Induction Conditioning HSCT type OS (days)
t
Autologous HSCT
M 89.3 NA NA auto-HSCT 219
M 68.6 *age-adapted hyper CVAD *HD BEAM auto-HSCT 174+
F 68.0 *hyper CVAD *HD BEAM auto-HSCT 887+
Allogeneic HSCT
M 40.9 *DAV 3+5+7 NA allo-HSCT 260
M 65.0 *MICE *S-HAM allo-HSCT 288
M 56.4 *GRAALL-2014/B RIC allo-HSCT 156+
M 45.0 *CHOEP NA allo-HSCT+DLI 1815+
M 25.7 *DAV 3+5+7 *FLAG allo-HSCT 2099+
F 30.3 *HOVON 102 MAC allo-HSCT 2283+
F 42.1 NA NA allo-HSCT LOF
M 68.9 gemcitabine NA allo-HSCT LOF
*Chemotherapy regimens are detailed in Supplementary 1. Abbreviations: OS, overall survival; 
M, male; F, female; NA, not available; RIC, reduced-intensity conditioning; DLI, donor lymphocyte 
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Figure Legends
Figure 1. 
Diversity of cutaneous BPDCN manifestations. (A) Multiple erythematous nodules on the 
chest and upper back. (B) Tumoral lesions on the face. (C) Bruise-like infiltrated patches 
on the back and right leg. (Photographs: Department of Dermatology, University Hospital 
of Zurich and Department of Dermatology, University Hospital Vienna). 
Figure 2. 
Comparison of logrank curves showing the survival (as percentage among all patients) of 
(A) of patients treated prior (n=11) vs. after (n=16) 2008 and (B) of patients who 
underwent AML- (n=5), ALL- (n=2) or lymphoma-regimens (n=12) of chemotherapy. 
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